|Bid||148.35 x 100|
|Ask||149.43 x 200|
|Day's Range||147.24 - 148.87|
|52 Week Range||128.81 - 155.86|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.06%|
The Federal Reserve typically hikes interest rates to obviate an overheating economy during the later stages of an economic cycle, typically foreshadowing the eventual end of a bull market. Nevertheless, ...
Globus Medical (GMED) recently launched a robotic surgical navigation device. Since its inception in 2003, Globus Medical has launched more than 180 products. Globus Medical acquired KB Medical, a Switzerland-based robotic developer, in June 2017.
Nektar Therapeutics (NKTR) has entered into a number of licensing and collaboration agreements for research, development, and commercialization with various healthcare companies, including Eli Lilly (LLY), AstraZeneca (AZN), and Amgen (AMGN). Under these agreements, Nektar is entitled to receive license fees, milestone payments, royalties, and payments for manufacturing and supplying Nektar’s proprietary PEGylation materials.
When it comes to investing, small-cap stocks beat large caps as the best ETFs to buy. After all, it’ll take a lot of a behemoth like International Business Machines Corp. (NYSE:IBM) to get the ship moving. Which is why small-cap stocks have tacked on an extra 253% in cumulative extra returns over large-cap stocks.
While risk-takers will eschew broader-scoped exchange-traded funds (ETFs) for the glory (and profits) of individual stocks, ETFs are a relevant component of any investing strategy. While the profit potential is greatest with a bet on a single company, the opposite is also true. Over the long run, the law of averages makes choosing the best Vanguard ETFs particularly compelling.
Stocks were mixed as Amgen and Celgene hurt biotechs, and ahead of ahead of Amazon and Alphabet's earnings after the close.
Key U.S. stock indexes sold off Wednesday as earnings reports continued and amid renewed talk about changes to 401(k) contribution limits.
Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.
Acadia Pharmaceuticals' (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.
In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).
Here's how exchange-traded funds work, why they benefit retail investors, and how to pick the right ETFs for your portfolio.
On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.
With arrival of spring comes first-quarter earnings announcements throughout the stock market. Large-cap companies generally report a little earlier, business results are better than 1Q's GDP might imply, and the news so far for both small- and ...
By Roger Nusbaum, AdvisorShares ETF Strategist The title of this post is a play on the bit in the movie Stripes when Bill Murray talks about dogs and cats living together. You probably heard about the niche ETF (naming names is difficult for ...
Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.